Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa-Reference-Cited by-同舟云学术

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Published:2017-03-14 Issue:1 Volume:65 Page:158-161
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Munita Jose M¹²³,Aitken Samuel L¹⁴,Miller William R¹²,Perez Federico⁵,Rosa Rossana⁶⁷,Shimose Luis A⁶⁷,Lichtenberger Paola N⁷,Abbo Lilian M⁶⁷,Jain Rupali⁸,Nigo Masayuki²,Wanger Audrey⁹,Araos Rafael³,Tran Truc T¹²,Adachi Javier¹⁰,Rakita Robert¹¹,Shelburne Samuel¹⁰,Bonomo Robert A⁵,Arias Cesar A¹²¹²

Affiliation:

1. Center for Antimicrobial Resistance and Microbial Genomics and Gulf Coast Consortium on Antimicrobial Resistance,

2. Division of Infectious Diseases, Department of Internal Medicine, and

3. Genomics and Resistant Microbes Group, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile;

4. Division of Pharmacy and

5. Cleveland Veterans Affairs Medical Center Case Western Reserve University, Ohio,

6. Department of Medicine, Jackson Memorial Hospital and

7. Division of Infectious Diseases, University of Miami Miller School of Medicine, Florida,

8. Department of Pharmacy and

9. Department of Pathology and Laboratory Medicine, University of Texas McGovern Medical School, Houston;

10. Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston,

11. Division of Allergy and Infectious Diseases, University of Washington, Seattle; and

12. International Center for Antimicrobial Resistance, Universidad El Bosque, Bogota, Colombia

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/65/1/158/24266222/cix014.pdf

Reference16 articles.

1. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations;van Duin;Clin Infect Dis,2016

2. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals;Sutherland;Clin Ther,2015

3. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012;Walkty;Antimicrob Agents Chemother,2013

4. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012);Farrell;Antimicrob Agents Chemother,2013

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

2. Role of β-lactamases and efflux pumps in multidrug resistance inPseudomonas aeruginosaisolated from patients in the Intensive Care Unit in the northeast of Brazil;2024-04-24

3. Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings—A French Real-world Study;Open Forum Infectious Diseases;2024-02-01

4. Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis;Enfermedades infecciosas y microbiologia clinica (English ed.);2023-10

5. Examining the role of glycoside hydrolases in local rheology of Pseudomonas aeruginosa biofilms;Frontiers in Physics;2023-09-07